RVU Stock Overview
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.
Ryvu Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł33.30|
|52 Week High||zł66.00|
|52 Week Low||zł22.20|
|1 Month Change||1.68%|
|3 Month Change||30.59%|
|1 Year Change||-43.08%|
|3 Year Change||-45.59%|
|5 Year Change||-26.20%|
|Change since IPO||516.67%|
Recent News & Updates
|RVU||PL Life Sciences||PL Market|
Return vs Industry: RVU underperformed the Polish Life Sciences industry which returned -36.8% over the past year.
Return vs Market: RVU underperformed the Polish Market which returned -36% over the past year.
|RVU Average Weekly Movement||13.9%|
|Life Sciences Industry Average Movement||7.1%|
|Market Average Movement||6.1%|
|10% most volatile stocks in PL Market||11.6%|
|10% least volatile stocks in PL Market||3.9%|
Stable Share Price: RVU is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: RVU's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
Ryvu Therapeutics Fundamentals Summary
|RVU fundamental statistics|
Is RVU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RVU income statement (TTM)|
|Cost of Revenue||zł13.23m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Nov 23, 2022
|Earnings per share (EPS)||-4.93|
|Net Profit Margin||-241.30%|
How did RVU perform over the long term?See historical performance and comparison
Is RVU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RVU?
Other financial metrics that can be useful for relative valuation.
|What is RVU's n/a Ratio?|
Price to Sales Ratio vs Peers
How does RVU's PS Ratio compare to its peers?
|RVU PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BML BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek
RVU Ryvu Therapeutics
Price-To-Sales vs Peers: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the peer average (14.7x).
Price to Earnings Ratio vs Industry
How does RVU's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Sales vs Industry: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the European Life Sciences industry average (4.4x)
Price to Sales Ratio vs Fair Ratio
What is RVU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||16.3x|
|Fair PS Ratio||7.8x|
Price-To-Sales vs Fair Ratio: RVU is expensive based on its Price-To-Sales Ratio (17.1x) compared to the estimated Fair Price-To-Sales Ratio (7.9x).
Share Price vs Fair Value
What is the Fair Price of RVU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Ryvu Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RVU's revenue is expected to decline over the next 3 years (-6.8% per year).
High Growth Revenue: RVU's revenue is forecast to decline over the next 3 years (-6.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RVU's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Ryvu Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RVU is currently unprofitable.
Growing Profit Margin: RVU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RVU is unprofitable, and losses have increased over the past 5 years at a rate of 53.3% per year.
Accelerating Growth: Unable to compare RVU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RVU is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.3%).
Return on Equity
High ROE: RVU has a negative Return on Equity (-59.93%), as it is currently unprofitable.
Discover strong past performing companies
How is Ryvu Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RVU's short term assets (PLN79.1M) exceed its short term liabilities (PLN24.4M).
Long Term Liabilities: RVU's short term assets (PLN79.1M) exceed its long term liabilities (PLN26.0M).
Debt to Equity History and Analysis
Debt Level: RVU has more cash than its total debt.
Reducing Debt: RVU's debt to equity ratio has reduced from 8.9% to 0.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RVU has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RVU is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
What is Ryvu Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Ryvu Therapeutics Dividend Yield vs Market|
|Company (Ryvu Therapeutics)||n/a|
|Market Bottom 25% (PL)||3.1%|
|Market Top 25% (PL)||9.5%|
|Industry Average (Life Sciences)||0.7%|
|Analyst forecast in 3 Years (Ryvu Therapeutics)||n/a|
Notable Dividend: Unable to evaluate RVU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RVU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RVU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVU's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RVU has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Pawel Tadeusz Przewiezlikowski, MSc., MBA, serves as the Chief Executive Officer of BioCentrum Sp. z o.o. Mr. Przewiezlikowski serves as a Member of Supervisory Board of SELVITA S.A.Mr. Przewiezlikow...
CEO Compensation Analysis
|Pawel Przewiezlikowski's Compensation vs Ryvu Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||zł524k||zł524k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||zł476k||zł476k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||zł655k||zł655k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||zł388k||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||zł426k||n/a|
Compensation vs Market: Insufficient data to establish whether Pawel's total compensation is reasonable compared to companies of similar size in the Polish market.
Compensation vs Earnings: Pawel's compensation has increased whilst the company is unprofitable.
Experienced Management: RVU's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Experienced Board: RVU's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Ryvu Therapeutics S.A.'s employee growth, exchange listings and data sources
- Name: Ryvu Therapeutics S.A.
- Ticker: RVU
- Exchange: WSE
- Founded: 2007
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł611.237m
- Shares outstanding: 18.36m
- Website: https://www.ryvu.com
Number of Employees
- Ryvu Therapeutics S.A.
- Leona Henryka Sternbacha 2
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RVU||WSE (Warsaw Stock Exchange)||Yes||Common Bearer Shares||PL||PLN||Jul 2011|
|9Y4||DB (Deutsche Boerse AG)||Yes||Common Bearer Shares||DE||EUR||Jul 2011|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.